These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 35577578)

  • 1. Hastening the Diagnosis of Amyotrophic Lateral Sclerosis.
    Mitsumoto H; Kasarskis EJ; Simmons Z
    Neurology; 2022 Jul; 99(2):60-68. PubMed ID: 35577578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potassium channel abnormalities are consistent with early axon degeneration of motor axons in the G127X SOD1 mouse model of amyotrophic lateral sclerosis.
    Maglemose R; Hedegaard A; Lehnhoff J; Dimintiyanova KP; Moldovan M; Grøndahl L; Meehan CF
    Exp Neurol; 2017 Jun; 292():154-167. PubMed ID: 28322742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phenotype of transgenic mice carrying a very low copy number of the mutant human G93A superoxide dismutase-1 gene associated with amyotrophic lateral sclerosis.
    Deitch JS; Alexander GM; Bensinger A; Yang S; Jiang JT; Heiman-Patterson TD
    PLoS One; 2014; 9(6):e99879. PubMed ID: 24945277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small molecules targeting different cellular pathologies for the treatment of amyotrophic lateral sclerosis.
    Elmansy MF; Reidl CT; Rahaman M; Özdinler PH; Silverman RB
    Med Res Rev; 2023 Nov; 43(6):2260-2302. PubMed ID: 37243319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early abnormalities in transgenic mouse models of amyotrophic lateral sclerosis.
    Durand J; Amendola J; Bories C; Lamotte d'Incamps B
    J Physiol Paris; 2006; 99(2-3):211-20. PubMed ID: 16448809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Motor neuron dysfunction in a mouse model of ALS: gender-dependent effect of P2X7 antagonism.
    Cervetto C; Frattaroli D; Maura G; Marcoli M
    Toxicology; 2013 Sep; 311(1-2):69-77. PubMed ID: 23583883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trehalose decreases mutant SOD1 expression and alleviates motor deficiency in early but not end-stage amyotrophic lateral sclerosis in a SOD1-G93A mouse model.
    Li Y; Guo Y; Wang X; Yu X; Duan W; Hong K; Wang J; Han H; Li C
    Neuroscience; 2015 Jul; 298():12-25. PubMed ID: 25841320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroprotective effects of JGK-263 in transgenic SOD1-G93A mice of amyotrophic lateral sclerosis.
    Ahn SW; Jeon GS; Kim MJ; Shon JH; Kim JE; Shin JY; Kim SM; Kim SH; Ye IH; Lee KW; Hong YH; Sung JJ
    J Neurol Sci; 2014 May; 340(1-2):112-6. PubMed ID: 24680562
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Kosuge Y; Kaneko E; Nango H; Miyagishi H; Ishige K; Ito Y
    Oxid Med Cell Longev; 2020; 2020():1020673. PubMed ID: 32089764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of the stress-activated MAP kinase, p38, but not JNK in cortical motor neurons during early presymptomatic stages of amyotrophic lateral sclerosis in transgenic mice.
    Holasek SS; Wengenack TM; Kandimalla KK; Montano C; Gregor DM; Curran GL; Poduslo JF
    Brain Res; 2005 May; 1045(1-2):185-98. PubMed ID: 15910777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Extracellular Cyclophilin A Reduces Neuroinflammation and Extends Survival in a Mouse Model of Amyotrophic Lateral Sclerosis.
    Pasetto L; Pozzi S; Castelnovo M; Basso M; Estevez AG; Fumagalli S; De Simoni MG; Castellaneta V; Bigini P; Restelli E; Chiesa R; Trojsi F; Monsurrò MR; Callea L; Malešević M; Fischer G; Freschi M; Tortarolo M; Bendotti C; Bonetto V
    J Neurosci; 2017 Feb; 37(6):1413-1427. PubMed ID: 28011744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gold Coast criteria expand clinical trial eligibility in amyotrophic lateral sclerosis.
    Jewett G; Khayambashi S; Frost GS; Beland B; Lee A; Hodgkinson V; Korngut L; Chhibber S
    Muscle Nerve; 2022 Oct; 66(4):397-403. PubMed ID: 35673968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delayed disease onset and extended survival in the SOD1G93A rat model of amyotrophic lateral sclerosis after suppression of mutant SOD1 in the motor cortex.
    Thomsen GM; Gowing G; Latter J; Chen M; Vit JP; Staggenborg K; Avalos P; Alkaslasi M; Ferraiuolo L; Likhite S; Kaspar BK; Svendsen CN
    J Neurosci; 2014 Nov; 34(47):15587-600. PubMed ID: 25411487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current State and Future Directions in the Therapy of ALS.
    Tzeplaeff L; Wilfling S; Requardt MV; Herdick M
    Cells; 2023 May; 12(11):. PubMed ID: 37296644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pericytes Extend Survival of ALS SOD1 Mice and Induce the Expression of Antioxidant Enzymes in the Murine Model and in IPSCs Derived Neuronal Cells from an ALS Patient.
    Coatti GC; Frangini M; Valadares MC; Gomes JP; Lima NO; Cavaçana N; Assoni AF; Pelatti MV; Birbrair A; de Lima ACP; Singer JM; Rocha FMM; Da Silva GL; Mantovani MS; Macedo-Souza LI; Ferrari MFR; Zatz M
    Stem Cell Rev Rep; 2017 Oct; 13(5):686-698. PubMed ID: 28710685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Development of motor neuron restorative therapy in amyotrophic lateral sclerosis using hepatocyte growth factor].
    Aoki M; Warita H; Suzuki N; Itoyama Y
    Rinsho Shinkeigaku; 2009 Nov; 49(11):814-7. PubMed ID: 20030218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Selenium-based compounds with therapeutic potential for SOD1-linked amyotrophic lateral sclerosis.
    Amporndanai K; Rogers M; Watanabe S; Yamanaka K; O'Neill PM; Hasnain SS
    EBioMedicine; 2020 Sep; 59():102980. PubMed ID: 32862101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guanabenz delays the onset of disease symptoms, extends lifespan, improves motor performance and attenuates motor neuron loss in the SOD1 G93A mouse model of amyotrophic lateral sclerosis.
    Jiang HQ; Ren M; Jiang HZ; Wang J; Zhang J; Yin X; Wang SY; Qi Y; Wang XD; Feng HL
    Neuroscience; 2014 Sep; 277():132-8. PubMed ID: 24699224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacotherapy for Amyotrophic Lateral Sclerosis: A Review of Approved and Upcoming Agents.
    Johnson SA; Fang T; De Marchi F; Neel D; Van Weehaeghe D; Berry JD; Paganoni S
    Drugs; 2022 Sep; 82(13):1367-1388. PubMed ID: 36121612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SA4503, a sigma-1 receptor agonist, suppresses motor neuron damage in in vitro and in vivo amyotrophic lateral sclerosis models.
    Ono Y; Tanaka H; Takata M; Nagahara Y; Noda Y; Tsuruma K; Shimazawa M; Hozumi I; Hara H
    Neurosci Lett; 2014 Jan; 559():174-8. PubMed ID: 24334165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.